Our overall goal is to serve the clinical and research PET/MR communities by providing access to state-of-the art PET/MR technology both on the software side (quantitation and reconstruction methods, kinetic modeling tools) as well as the hardware/radiochemistry versant (micro-coils, dual PET-MR probes).
Our service activities can be described in three categories: 1) Regional service that enables clinical and pre-clinical PET/MR research; 2) On-site service that enables the deployment of specific software and radiopharmaceuticals using physical resources such as radiopharmacy labs, PET/MR scanner, supercomputers with very large flat physical memory; and 3) Electronic support for research using the electronically downloadable software that will be developed for motion, attenuation and PSF quantitation, PET/MR reconstruction, kinetic modeling, etc.
|Service Project Title||Service Project Partner Interaction||Institution/Department||Service partner Funding # Period of Funding|
|Targeting Choline Phospholipid Metabolism in Lymphangioleiomyomatosis||Carmen Priolo* (TR&D 3)||Brigham & Women’s Hospital Medicine, Pulmonary & Critical Care||R01HL130336 12/2015 – 11/2021|
|Neurobiological underpinnings of placebo response in depression||Maurizio Fava Cristina Cusin* Diego Pizzagalli (TR&D 1,2,3)||McLean Hospital; Massachusetts General Hospital Psychiatry||R01MH102279 6/2015 – 6/2021|
|Exploiting Ferroportin for Cancer Imaging and Therapy||Jan Grimm (TR&D 3)||Memorial Sloan Kettering Nuclear Medicine||R01CA218615 6/2017 – 6/2022|
|Football Players Health’s Study at Harvard||Ross Zafonte (TR&D 1,2,3)||Spaulding Rehabilitation Network Physical Medicine & Rehabilitation||Football Player Association 6/2016 – 6/2022|
|Ravinder Ragetti (TR&D 1,2)||NYU Langone Health Radiology|
|Ultra-high resolution brain PET scanner for in-vivo autoradiography imaging||Roger Lecomte (TR&D 1,2,3)||University of Sherbrooke Nuclear Medicine & Radiobiology||U01EB027003 9/2018 – 6/2023|
|Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy||Anna-Liisa Brownell* (TR&D 1,2,3)||Massachusetts General Hospital Radiology||CDMRP – W81XWH-17-1-0228 6/2017 – 6/2021|
|Imaging Tau, Amyloid, and Neurodegeneration in PPA||Bradford Dickerson (TR&D 1,2,3)||Massachusetts General Hospital Neurology||R01DC014296 9/2016 – 8/2021|
|Improving early disease detection and imaging with MRI nanotechnology||Zdenka Kuncic* (TR&D 3)||University of Sydney Institute of Nanoscale Science and Technology||Australian Academy of Technology and Engineering (ASTE) 6/2018 – 6/2020|
|PET/MR mapping of myocardial membrane potential||Georges El Fakhri (TR&D 1,2)||Massachusetts General Hospital Radiology||R01HL137230 9/2017 – 6/2022|
|Motion-Compensated Simultaneous MRI and PET Imaging||Roger Fulton (TR&D 1,2)||University of Sydney / Brain & Mind Institute||Australian Research Council (ARC)|